



UNIVERSITÀ  
DEGLI STUDI  
FIRENZE

## FLORE

# Repository istituzionale dell'Università degli Studi di Firenze

### **May TGFBR1 act also as low penetrance allele in marfan syndrome?**

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

*Original Citation:*

May TGFBR1 act also as low penetrance allele in marfan syndrome? / Lucarini L; Evangelisti L; Attanasio M; Lapini I; Chiarini F; Porciani MC; Abbate R; Gensini G; Pepe G. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - STAMPA. - 131:(2009), pp. 281-284.

*Availability:*

This version is available at: 2158/369053 since:

*Terms of use:*

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

*Publisher copyright claim:*

(Article begins on next page)

## May TGFBR1 act also as low penetrance allele in Marfan syndrome?

Laura Lucarini<sup>a,\*</sup>, Lucia Evangelisti<sup>a</sup>, Monica Attanasio<sup>a</sup>, Ilaria Lapini<sup>a</sup>, Francesca Chiarini<sup>a</sup>,  
Maria Cristina Porciani<sup>a</sup>, Rosanna Abbate<sup>a</sup>, GianFranco Gensini<sup>a,b</sup>, Guglielmina Pepe<sup>a</sup>

<sup>a</sup> Department of Medical and Surgical Critical Care, University of Florence; Marfan Centre, Azienda Ospedaliero-Universitaria Careggi, Florence; Center for the Study at Molecular and Clinical Level of Chronic, Degenerative and Neoplastic Diseases to Develop Novel Therapies, University of Florence, Florence, Italy

<sup>b</sup> Fondazione Don Carlo Gnocchi ONLUS, Centro S.Maria degli Ulivi-IRCCS, Florence, Italy

Received 31 May 2007; accepted 1 July 2007

Available online 22 October 2007

### Abstract

Marfan syndrome, a human disease involving cardiovascular and skeletal apparatuses and ocular and central nervous systems, is associated to mutations in *FBNI* gene; heterozygous mutations in *TGFBR2* and *TGFBR1* genes were found associated to MFS type 2, characterized by the presence of skeletal and cardiovascular major criteria and absence of eye major criterion.

We screened the *TGFBR1* gene in 46 Marfan patients in whom mutations in *FBNI* and *TGFBR2* genes were excluded and the analysis of Ex1 was extended to additional 114 Marfan patients and 237 controls.

We detected two potentially pathological sequence variants: the TGFBR1 6Ala allele whose frequency was higher in the group of Marfan patients (0.13) than in the controls (0.08) ( $p=0.013$ ; OR=1.69) and an insertion of 20 nucleotides in the 5'UTR that turned out to be a familial silent rare polymorphism. We hypothesize that TGFBR1 sequence variants may act not only as major, but also as low penetrance alleles of the clinical phenotype in Marfan syndrome.

© 2007 Elsevier Ireland Ltd. All rights reserved.

**Keywords:** *TGFBR1*; Marfan syndrome; MFS type 2; TGFBR1 6Ala allele

Marfan syndrome (MFS; MIM#154700) is a multisystemic dominantly inherited connective tissue disorder with a prevalence of 1 in 5000–10000 [1]; MFS is mostly caused by mutations in fibrillin-1 (*FBNI*; MIM#134797; chr.15q21.1) [2]. MFS type 2 (MFS2; MIM#154705) is characterized by absence of major ocular involvement; it has been recently associated to heterozygous dominant mutations in both *TGFBR2* (MIM#190182; chr.3p22) [3–5], and *TGFBR1* (MIM#190181; chr.9q33–34) [4,5], the two genes coding for the receptors of transforming growth factor beta (TGF $\beta$ ). TGF $\beta$  induces extracellular matrix (ECM) formation by binding to its two receptors and by activating the intracellular signalling through SMAD proteins [6]. Mutations in *FBNI*, *TGFBR1* and *TGFBR2* lead to altered TGF $\beta$  signalling resulting in degenerative changes of the ECM and causing aneurysms and dissections of the vessel wall in MFS2 [3,7], Thoracic Aortic Aneurysms and Dissections (TAAD; MIM#608967) [4,7], and Loeys–Dietz syndrome (LDS;

MIM#609192) [5,8,9]. Noteworthy, in a mouse model of MFS, excessive TGF $\beta$  signalling was demonstrated to contribute to the formation of aortic aneurysms; furthermore, treatment with TGF $\beta$  antagonists was shown to block and reverse the demolition of ECM and consequentially the dilatation and dissection of aorta [10].

We investigated 46 MF patients (34 men and 12 women, median age 32.5 years, range 7–54 years) diagnosed according to Ghent criteria, referred to the Center for Marfan Syndrome and Related Disorders of the Azienda Ospedaliero-Universitaria, Careggi, University of Florence.

DNA mutation analysis of *FBNI* [11], *TGFBR2* [3] and *TGFBR1* genes (Table 1) was performed [11,12]. Clinical characteristics and molecular data of these patients (8 of them with MFS2) are shown in Table 2. No mutations in both *FBNI* and *TGFBR2* were found. We detected two potentially pathological mutations both in exon 1 of *TGFBR1*. In order to verify their pathogenicity, we extended the analysis to 114 Marfan patients (69 men and 45 women, median age 35.5 years, range 7–70 years; 18 MFS2, 103 carrying a mutation in *FBNI*) and 237 healthy unrelated controls (111 men and 126 women, median age 51.2 years, range 15–91 years) with primers Ex1ins and Ex1-9\* (Table 1). The different alleles were separated on a 4% agarose gel. Patients and controls, all Italian, gave their

\* Corresponding author. Department of Medical and Surgical Critical Care, University of Florence, Viale Morgagni 85, 50134 Florence, Italy. Tel.: +39 055 7949420; fax: +39 055 7949418.

E-mail address: lauralucarini@gmail.com (L. Lucarini).

Table 1  
Primers of TGFBR1 gene

TGFBR1 gene	Forward	Reverse	TM	Size (bp)
EX1	5'-agc agt tac aaa ggg cgc g-3'	5'-gcg cca tgt ttg aga aag ag-3'	60 °C	313
EX1ins	5'-gga cgc gcg tcc tcc gag c-3'	5'-gac cgc cgc ctc cat ggt c-3'	62 °C	157
EX1-9*	5'-gac cat gga ggc ggc ggt c-3'	5'-gtc gcc ccc ggg agc ag-3'	62 °C	99
EX2	5'-gag caa caa aca gtg cat aga aa-3'	5'-tcc ctt cca gtt cta aaa tca ca-3'	58 °C	448
EX3	5'-ggc tct ttg gct aag tgg tg-3'	5'-ttc tag caa gtt ggc tta tta g-3'	58 °C	449
EX4a	5'-tca gtt ttc tgg gtc act cat t-3'	5'-gtt ctt ctc tag agg aga ata tc-3'	58 °C	237
EX4b	5'-ggt tgg aga gga aag tgg c-3'	5'-gtc tca tct act ttg atg atg g-3'	56 °C	228
EX5	5'-ttg cag tgt gtg act cag ga-3'	5'-agg ccc agc ctc cac ctt-3'	60 °C	351
EX6	5'-ttt ggg ttg gga gaa gag ac-3'	5'-ttt ggg ttg gga gaa gag ac-3'	58 °C	399
EX7	5'-tgt ctg aaa gga ggt tca tcc-3'	5'-aat tct tga aca act tct gct c-3'	60 °C	256
EX8	5'-gcc ttg gca tta gct gaa taa-3'	5'-cat tgg ttt gac tgc tat gaa aa-3'	58 °C	316
EX9a	5'-cgt aaa aat tct tat cca gac c-3'	5'-cct tct gtt ccc tct cag tg-3'	60 °C	300
EX9b	5'-ctt cag atc tgc tcc tgg g-3'	5'-cat tca aag tct gaa tca agg-3'	60 °C	429
EX9c	5'-gta cat tct cag agg att ctg-3'	5'-gaa tac caa atg aca tac cac-3'	60 °C	403

\* = primers modified from [13].

Accession number NC\_000009.10 for TGFBR1 gDNA.

informed consent and the study was approved by the local ethics committee of the Faculty of Medicine, University of Florence.

The 6Ala allele polymorphism in Ex1 (Fig. 1; Table 3a) [5,13] was a trinucleotide GCG, corresponding to alanine (Ala), repeated 6 or 9 times. The 6Ala allele was the rare variant (Fig. 2).

The heterozygous insertion of 20nts in Ex1-5'UTR (Fig. 1; Table 3a) was identified in the proband, his healthy son, and an affected niece of one Marfan family. It was a duplication of 20nts (nts 3–22), inserted between nts 22 and 23 of exon 1, 55nts before the ATG start of protein translation. It is located in a sequence that does not seem to contain any site for transcription binding proteins




Fig. 1. Sequence variants found in Exon 1 of TGFBR1: A: insertion of the 20 duplicated nucleotides in the Ex1-5'UTR; B: the TGFBR1 6Ala allele is indicated and the 9nts (3Ala) deleted in the polymorphism are highlighted. Nts = nucleotides; AA = aminoacids; Ala = alanine.

Genotype distribution and allele frequency were in Hardy–Weinberg equilibrium for the 6Ala allele polymorphism both in patients and controls. A 9Ala/7Ala genotype was detected in one control.

The 6Ala allele frequency significantly differed between the group of Marfan patients and controls ( $p=0.013$ ;  $0.13$  vs.  $0.08$ ). The genotype distribution of the 6Ala allele polymorphism was higher in the group of Marfan patients (9Ala/6Ala 21.9% and 6Ala/6Ala 2.5%) than in the controls (9Ala/6Ala 16%). Furthermore, the homozygous genotype 6Ala/6Ala was detected only in 4 MF patients (Table 3b). The odds ratio was 1.69 (95%CI:1.023–2.785), suggesting that the 6Ala allele may contribute to Marfan syndrome phenotype.

The 6Ala allele frequency was 0.13 in both classic MFS and MFS2, although the second group is still too small. No significant different distribution of the 6Ala allele was found between sexes and between single systems or organs' involvement.




Fig. 2. PCR fragments of homozygous and heterozygous genotypes of TGFBR1 6Ala allele polymorphism and homozygous genotype of normal TGFBR1 9Ala allele on agarose gel (4%). Lanes 1 and 6 = molecular markers; lanes 2 and 5 = 9Ala/9Ala genotype; lane 3 = 9Ala/6Ala genotype; lane 4 = 6Ala/6Ala genotype. 9Ala = 319 bp; 6Ala = 310 bp. Ala = alanine; bp = base pairs.

Table 2  
Clinical manifestations and mutations found in 46 Marfan patients

	Age (yrs)	Sex	Major criteria			Minor criteria				TGFBR1 6Ala genotype
			Familial history	CV	Ocular	Skel	Skin	Pneum		
1	36	F	+	-	+	+	+	-	9Ala/9Ala	
2	35	M	+	+	-	-	+	-	9Ala/9Ala	
3	38	M	-	§	+	+	-	-	9Ala/9Ala	
4	42	M	-	*	+	-	+	-	9Ala/9Ala	
5	46	M	-	*	+	-	+	-	9Ala/9Ala	
6	46	F	-	+	+	+	+	-	9Ala/9Ala	
7	40	M	-	§	+	+	+	-	9Ala/9Ala	
8	11	M	-	+	+	-	-	-	9Ala/9Ala	
9	34	F	+	§	+	+	+	-	<b>9Ala/6Ala</b>	
10	24	M	-	§	+	-	+	+	9Ala/9Ala	
11	8	M	-	+	+	-	-	-	9Ala/9Ala	
12	23	F	+	§	+	-	+	-	9Ala/9Ala	
13	44	M	+	+	-	-	+	-	9Ala/9Ala	
14	13	M	+	+	+	+	-	-	9Ala/9Ala	
15	30	M	+	+	-	-	+	-	9Ala/9Ala	
16	42	M	+	+	-	-	+	-	9Ala/9Ala	
17	40	M	+	+	+	-	+	-	9Ala/9Ala	
18	33	F	+	+	+	-	-	-	9Ala/9Ala	
19	36	M	+	+	-	-	+	-	<b>9Ala/6Ala</b>	
20	42	M	-	§	+	-	+	-	<b>9Ala/6Ala</b>	
21	25	F	+	-	-	+	+	-	9Ala/9Ala	
22	22	M	-	+	+	-	+	-	9Ala/9Ala	
23	34	F	-	+	+	-	-	-	9Ala/9Ala	
24	30	M	-	*	+	-	+	-	9Ala/9Ala	
25	34	F	-	+	+	-	-	-	9Ala/9Ala	
26	42	M	-	+	+	-	-	-	9Ala/9Ala	
27	30	M	-	*	+	-	+	-	9Ala/9Ala	
28	44	M	+	+	-	-	+	-	9Ala/9Ala	
29	45	M	+	+	-	-	+	-	ins 20nts hetero 9Ala/9Ala	
30	32	M	-	*	+	-	+	-	9Ala/9Ala	
31	33	F	-	*	+	-	+	-	<b>9Ala/6Ala</b>	
32	40	M	-	*	+	-	+	-	9Ala/9Ala	
33	45	M	-	*	+	-	+	-	9Ala/9Ala	
34	39	F	-	*	+	-	+	-	<b>9Ala/6Ala</b>	
35	20	F	-	+	+	-	+	-	9Ala/9Ala	
36	15	M	-	*	+	-	+	-	<b>9Ala/6Ala</b>	
37	40	M	-	*	+	-	+	-	9Ala/9Ala	
38	9	M	-	+	+	-	-	-	9Ala/9Ala	
39	28	M	-	*	+	-	+	-	9Ala/9Ala	
40	25	M	+	+	-	-	+	-	9Ala/9Ala	
41	7	M	-	§	+	-	+	-	9Ala/9Ala	
42	32	M	+	+	-	-	+	-	9Ala/9Ala	
43	54	F	-	§	+	-	+	-	9Ala/9Ala	
44	44	M	+	+	+	-	+	-	9Ala/9Ala	
45	22	M	+	+	-	-	+	-	<b>6Ala/6Ala</b>	
46	43	M	+	+	+	+	+	-	9Ala/6Ala	

Wt = wild type; yrs = years; M = male; F = female; CNS = central nervous system; CV = cardiovascular system; skel = skeletal system; Pneum = pneumothorax; \* = presence of dural ectasia, required for diagnosis of Marfan; § = diagnosis of MFS2. Data in bold indicates patients with the polymorphism.

nor translational regulatory sequences; therefore, this may be considered a "silent" and private rare polymorphism.

The frequencies of three known polymorphisms appeared to be higher in patients than in controls (Table 4).

*In vitro* studies on TGF $\beta$  type I receptor showed that the molecular differences between 6Ala and 9Ala are due to altered 6Ala signal sequence; this mechanism may result

either from direct transcriptional inactivation or from alterations of TGF $\beta$  signalling pathways [14]. The 6Ala signal sequence could directly interact with regulatory elements of the signalling pathway genes [14].

A highly significant association between the 6Ala allele of *TGFBR1* gene and patients with Marfan syndrome is here demonstrated for the first time; moreover, homozygosity for

Table 3a  
Modifier mutations in TGFBR1 gene in Marfan patients and healthy controls

EX/IVS	Position (nt)	Status	Status	Patients (n=160)	Genotype distribution	Controls (n=237)	Genotype distribution
Ex1-5'UTR	ins 20nts (22/23)	Novel	Hetero	1	ins=0.006	0	ins=0
Ex1	del 9nts (146-154)	Known <sup>a</sup>	Homo	4	6Ala/6Ala=0.025	0	9Ala/6Ala=0.16 <sup>b</sup>
			Hetero	35	9Ala/6A=0.219	38	

<sup>a</sup> [13].

<sup>b</sup> Frequency from literature (9Ala/6A=0.14).

Table 3b  
TGFBR1 6Ala genotype distribution and allele frequency in MFS patients *versus* controls

Genotype distribution	MFS patients (n=160)	Controls (n=237)	p
TGFBR1 6Ala polymorphism			
9Ala/9Ala	121 (75.6%)	199 (84.0%)	
9Ala/6Ala	35 (21.9%)	38 (16.0%)	
6Ala/6Ala	4 (2.5%)	0	0.014 <sup>a</sup>
TGFBR1 6Ala allele frequency	0.13	0.08	0.013 <sup>b</sup>

<sup>a</sup> Genotype distribution.

<sup>b</sup> Allele frequency.

Table 4  
Polymorphisms in TGFBR1 gene in Marfan patients and healthy controls

EX/IVS	Position (nt)	Status	Status	Patients (n=46)	Genotype distribution	Controls (n=92)	Genotype distribution
IVS7	+24 G>A	Novel	Hetero	16	A=0.35	26	A=0.28
IVS8	del 5nts+(90-94)	Novel	Hetero	16	del=0.35	25	del=0.27
Ex9-3'UTR	+69 A>G	Known <sup>a</sup>	Hetero	13	G=0.28	25	G=0.27

nt = nucleotide; ins = insertion; del = deletion.

<sup>a</sup> [5].

the 6Ala allele was found only in patients. For this reason, at the moment it may be defined as a low penetrance allele. A larger number of patients is required to investigate the possibility that 6Ala allele may act as modifier mutation.

## References

- Judge DP, Dietz HC. Marfan's syndrome. *Lancet* 2005;366:1965-76.
- Collod-Beroud G, Le Bourdelles S, Ades L, et al. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. *Hum Mutat* 2003;22:199-208.
- Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in Marfan syndrome. *Nat Genet* 2004;36:855-60.
- Matyas G, Arnold E, Carrel T, et al. Identification and in silico analyses of novel TGFBR1 and TGFBR2 mutations in Marfan syndrome-related disorders. *Hum Mutat* 2006;27:760-9.
- Singh KK, Rommel K, Mishra A, et al. TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome. *Hum Mutat* 2006;27:770-7.
- Lu SL, Kawabata M, Imamura T, Miyazono K, Yuasa Y. Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene. *Biochem Biophys Res Commun* 1999;259:385-90.
- Pannu H, Fadulu VT, Chang J, et al. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. *Circulation* 2005;112:513-20.
- Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. *Nat Genet* 2005;37:275-81.
- Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. *N Engl J Med* 2006;355:788-98.
- Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. *Science* 2006;312:117-21.
- Pepe G, Giusti B, Evangelisti L, et al. Fibrillin-1 (FBN1) gene frameshift mutations in Marfan patients: genotype-phenotype correlation. *Clin Genet* 2001;59:444-50.
- Giusti B, Lucarini L, Pietroni V, et al. Dominant and recessive COL6A1 mutations in Ullrich scleroatonic muscular dystrophy. *Ann Neurol* 2005;58:400-10.
- Pasche B, Luo Y, Rao PH, et al. Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. *Cancer Res* 1998;58:2727-32.
- Pasche B, Knobloch TJ, Bian Y, et al. Somatic acquisition and signaling of TGFBR1\*6A in cancer. *JAMA* 2005;294:1634-46.